Literature DB >> 19863710

Continuous intrathecal baclofen for children with spasticity and/or dystonia: Goal attainment and complications associated with treatment.

Anna Ward1, Suzie Hayden, Mark Dexter, Adam Scheinberg.   

Abstract

AIM: To describe complications and outcomes of intrathecal baclofen (ITB) therapy in children with spasticity and/or dystonia.
METHODS: A prospective study of goal attainment after ITB therapy and a retrospective review of medical records for complications. The children were described as dystonia-predominant or spasticity-predominant and the subgroups were compared. Goals were assessed at baseline and goal attainment at 6 months post-implant. Data were analysed using Wilcoxon signed-rank test. The patients' goals were measured with the Canadian Occupational Performance Measure (COPM) and goal attainment scaling (GAS). Complication rates were calculated by dividing the number of complications by the duration of pump implantation.
RESULTS: Twenty-five children were included, 16 with complete goal attainment data. The mean age was 10 years and 3 months. Eighty-eight percent had a diagnosis of cerebral palsy. The most common goals were improved positioning and transfers. A statistically significant increase (P < 0.001) in both domains of the COPM was demonstrated. The mean GAS T-score was significantly higher at 6 months post implant (P < 0.001). Seventy percent of the subjects achieved their goals at 6 months. The complication rate was 0.38 per year of pump operation, higher in subjects with dystonia (0.71) compared with those with spasticity (0.25).
CONCLUSIONS: ITB results in statistically significant levels of satisfaction and goal attainment in children with spasticity and/or dystonia. GAS was a useful measure of goal attainment. While, ITB is effective for children with spasticity and dystonia, those with dystonia have a higher rate of complications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863710     DOI: 10.1111/j.1440-1754.2009.01601.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  7 in total

1.  Intrathecal baclofen therapy for spasticity of cerebral origin--does the position of the intrathecal catheter matter?

Authors:  Gnanamurthy Sivakumar; Yoong Yap; Mekidm Tsegaye; Michael Vloeberghs
Journal:  Childs Nerv Syst       Date:  2010-03-20       Impact factor: 1.475

2.  Intrathecal baclofen therapy: complication avoidance and management.

Authors:  Neil Haranhalli; Dhanya Anand; Jeffrey H Wisoff; David H Harter; Howard L Weiner; Michelle Blate; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2010-09-18       Impact factor: 1.475

Review 3.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

4.  Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.

Authors:  Kirsty Stewart; Gavin Hutana; Megan Kentish
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

Review 5.  Intrathecal baclofen for treating spasticity in children with cerebral palsy.

Authors:  Monika J Hasnat; James E Rice
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

6.  Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial: the IDYS trial.

Authors:  Laura A Bonouvrié; Jules G Becher; Johannes S H Vles; Karin Boeschoten; Dan Soudant; Vincent de Groot; Willem J R van Ouwerkerk; Rob L M Strijers; Elisabeth Foncke; Joke Geytenbeek; Peter M van de Ven; Onno Teernstra; R Jeroen Vermeulen
Journal:  BMC Pediatr       Date:  2013-10-28       Impact factor: 2.125

7.  The Effect of Intrathecal Baclofen in Dyskinetic Cerebral Palsy: The IDYS Trial.

Authors:  Laura A Bonouvrié; Jules G Becher; Johan S H Vles; R Jeroen Vermeulen; Annemieke I Buizer
Journal:  Ann Neurol       Date:  2019-05-21       Impact factor: 10.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.